RxDoctor Payments Data

Mojgan Sadeghi, MD

Family Medicine · Simi Valley, CANPI 1942318902

Payments from drug & device makers

$1,523in general payments, 2019–2025

Across 63 payments — averaging $24.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$294
  • Otsuka America Pharmaceutical, Inc.$221
  • Merck$180
  • Intuitive Surgical$96
  • Pfizer$69
  • Kowa Pharmaceuticals America, Inc.$57
  • plus $607 from 20 others

What the payments were for

  • Food & beverage$1,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,523 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$154,771
Medicare patients
165
Services billed
6,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$69,282
FarxigaDapagliflozin Propanediol26$28,921
JanuviaSitagliptin Phosphate17$14,665
XareltoRivaroxaban15$12,389
LinzessLinaclotide11$6,455
Spiriva RespimatTiotropium Bromide12$5,398
Breo ElliptaFluticasone/Vilanterol11$3,805
Atorvastatin Calcium599$3,530
Ibandronate Sodium102$2,735
SynthroidLevothyroxine Sodium40$2,326
Losartan Potassium360$2,250
Varenicline Tartrate11$2,019
Levothyroxine Sodium287$1,990
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$1,758
Albuterol Sulfate HfaAlbuterol Sulfate77$1,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$69$70,71185 claims
AstraZenecaFarxiga$294$28,92126 claims
MerckJanuvia$180$14,66517 claims
AbbVieLinzess, Synthroid$16$8,78151 claims
Boehringer IngelheimSpiriva Respimat$52$5,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Simi Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →